Manufacturer of Controlled Substances; Notice of Registration, 17124 [05-6592]

Download as PDF 17124 Federal Register / Vol. 70, No. 63 / Monday, April 4, 2005 / Notices of Diversion Control, Drug Enforcement Administration that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. Dated: March 25, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–6592 Filed 4–1–05; 8:45 am] Dated: March 25, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–6585 Filed 4–1–05; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Manufacturer of Controlled Substances; Notice of Application DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated December 21, 2004, and published in the Federal Register on January 4, 2005, (70 FR 390), Cedarburg Pharmaceuticals, Inc., 870 Badger Circle, Grafton, Wisconsin 53024, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedule II: Schedule Dihydrocodeine (9120) ................. Remifentanil (9739) ...................... Sufentanil (9740) .......................... II II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cedarburg Pharmaceuticals, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Cedarburg Pharmaceuticals, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33(a), the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. VerDate jul<14>2003 15:19 Apr 01, 2005 Jkt 205001 Drug Drug Enforcement Administration BILLING CODE 4410–09–P Drug (CFR), this is notice that on January 4, 2005, Mallinckrodt Inc., Mallinckrodt & Second Streets, St. Louis, Missouri 63147, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedules I and II: Pursuant to 21 CFR 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on February 7, 2005, Johnson Matthey, Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066, made application by letter to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of Methamphetamine (1105), a basic class of controlled substance listed in Schedule II. The company plans to manufacture the listed controlled substance in bulk for distribution to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than June 3, 2005. Dated: March 25, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–6586 Filed 4–1–05; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to section 1301.33(a) of Title 21 of the Code of Federal Regulations PO 00000 Frm 00075 Fmt 4703 Sfmt 4703 Tetrahydrocannabinols (7370) ..... Codeine-N-oxide (9053) ............... Dihydromorphine (9145) ............... Difenoxin (9168) ........................... Heroin (9200) ............................... Morphine-N-oxide (9307) ............. Nicomorphine (9312) .................... Normorphine (9313) ..................... Norlevorphanol (9634) .................. Amphetamine (1100) .................... Methamphetamine (1105) ............ Methylophenidate (1724) .............. Codeine (9050) ............................. Diprenorphine (9058) ................... Etorphine HCL (9059) .................. Dihydrocodeine (9120) ................. Hydromorphone (9150) ................ Oxycodone (9143) ........................ Diphenoxylate (9170) ................... Benzoylecgonine (9180) ............... Hydrocodone (9193) ..................... Levorphanol (9220) ...................... Meperidine (9230) ........................ Methadone (9250) ........................ Methadone Intermediate (9254) ... Metopon (9260) ............................ Dextropropoxyphene (9273) ......... Morphine (9300) ........................... Thebaine (9333) ........................... Opium extracts (9610) .................. Opium fluid extract (9620) ............ Opium tincture (9630) .................. Opium, powdered (9639) ............. Opium, granulated (9640) ............ Levo-alphacetylmethadol (9648) .. Oxymorphone (9652) ................... Alfentanil (9737) ........................... Remifentanil (9739) ...................... Sufentanil (9740) .......................... Fentanyl (9801) ............................ Schedule I I I I I I I I I II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II The company plans to manufacture the listed controlled substances for internal use and for distribution to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to E:\FR\FM\04APN1.SGM 04APN1

Agencies

[Federal Register Volume 70, Number 63 (Monday, April 4, 2005)]
[Notices]
[Page 17124]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-6592]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated December 21, 2004, and published in the Federal 
Register on January 4, 2005, (70 FR 390), Cedarburg Pharmaceuticals, 
Inc., 870 Badger Circle, Grafton, Wisconsin 53024, made application by 
letter to the Drug Enforcement Administration (DEA) to be registered as 
a bulk manufacturer of the basic classes of controlled substances 
listed in Schedule II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Dihydrocodeine (9120)......................  II
Remifentanil (9739)........................  II
Sufentanil (9740)..........................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for distribution to its customers.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Cedarburg Pharmaceuticals, Inc. to manufacture the listed basic classes 
of controlled substances is consistent with the public interest at this 
time. DEA has investigated Cedarburg Pharmaceuticals, Inc. to ensure 
that the company's registration is consistent with the public interest. 
The investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 
21 CFR 1301.33(a), the above named company is granted registration as a 
bulk manufacturer of the basic classes of controlled substances listed.

    Dated: March 25, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 05-6592 Filed 4-1-05; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.